Neurocrine biosciences to present ongentys® (opicapone) and ingrezza® (valbenazine) data at the american neurological association 2021 virtual annual meeting

San diego, oct. 16, 2021 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced that it will present key information from its movement disorder treatments for parkinson's disease and tardive dyskinesia (td) at the american neurological association (ana) 2021 virtual annual meeting being held october 17–19, 2021. neurocrine biosciences will present new post-hoc analysis of pooled data from the ongentys® (opicapone) bipark-1 and bipark-2 phase 3 studies evaluating nighttime "off" episodes in people with parkinson's disease and motor fluctuations.
NBIX Ratings Summary
NBIX Quant Ranking